Granules India Secures Sole First-to-File Status for Generic Sodium Oxybate Oral Suspension MM Desk 15 July, 2026 Granules India Limited has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application Read More
Granules Life Sciences Receives VAI Classification from US FDA Following Inspection of Telangana Facility MM Desk 2 April, 2026 Granules India Limited has announced that its wholly owned subsidiary, Granules Life Sciences Private Limited Read More
Granules Pharmaceuticals Receives FDA Tentative Approval with 180-Day Exclusivity for Generic ADHD Treatment MM Desk 9 January, 2026 Granules Pharmaceuticals, Inc, a wholly owned subsidiary of Granules India Limited, has received tentative approval Read More
Granules Pharma Gets USFDA Tentative Approval for Generic ADHD Therapy MM Desk 2 January, 2026 Granules Pharmaceuticals Inc, a wholly owned subsidiary of Granules India Limited, has received tentative approval Read More